BioSpace News Archive

Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company developing N-myristoyltransferase (NMT) inhibitors as targeted therapies for the treatment of hematologic cancers and solid tumors.

Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB, announced the presentation of three abstracts that highlights data from its myelofibrosis treatment option at the American Society of Clinical Oncology Annual Meeting taking place in Chicago from May 31 – June 4, 2024.

Inhibrx, Inc. announced that, at a special meeting, the Company’s stockholders approved the sale to Sanofi of all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency.

Scinai Immunotherapeutics Ltd. announced the receipt of an additional Nasdaq Staff determination letter regarding noncompliance with the minimum shareholders’ equity required for continued listing and a hearing with the Nasdaq Hearings Panel to present a plan for the Company to regain compliance.

Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients

AmerisourceBergen Specialty Group, LLC is issuing notice to individuals who may have been impacted by a data security incident.

FSD Pharma Inc. is pleased to announce that it has entered into an investor relations services agreement with IR Agency LLC effective May 22, 2024.

NLS Pharmaceutics Ltd. announced that on May 22, 2024, the Company received an additional staff determination letter from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it did not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing set forth in Listing Rule 5550, and that the additional delinquency may serve as a separate basis for the delisting of the Company’s securities from Nasdaq.

Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces a publication in the Journal of Molecular Metabolism.

Nicox SA, an international ophthalmology company, convenes an ordinary shareholder meeting on Friday June 28th, 2024 at 2:30 pm CEST in the offices of BuroClub – Drakkar 2 – Bâtiment D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France.